A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2011-09-21
- Lead Sponsor
- Edusa Pharmaceuticals, Inc.
- Registration Number
- NCT01161602
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath